SEARCH OUR PRODUCT CATALOG

VCL-FGFR2 Fusion FISH Probe

The VCL-FGFR2 Fusion FISH Probe is used to confirm a fusion of the VCL and FGFR2 genes. The fusion of the VCL and FGFR2 genes has been associated with Thyroid Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.

** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.

Turnaround Time: 7-10 Business Days    Shipping Time: 1-2 Day Expedited Shipping

SKU Test Kits Buffer Dye Color Order Now
VCL-FGFR2-20-ORGR  (Standard Design) 20 (40 μL) 200 μL
VCL-FGFR2-20-RERE 20 (40 μL) 200 μL
VCL-FGFR2-20-REOR 20 (40 μL) 200 μL
VCL-FGFR2-20-REGO 20 (40 μL) 200 μL
VCL-FGFR2-20-REGR 20 (40 μL) 200 μL
VCL-FGFR2-20-REAQ 20 (40 μL) 200 μL
VCL-FGFR2-20-ORRE 20 (40 μL) 200 μL
VCL-FGFR2-20-OROR 20 (40 μL) 200 μL
VCL-FGFR2-20-ORGO 20 (40 μL) 200 μL
VCL-FGFR2-20-ORAQ 20 (40 μL) 200 μL
VCL-FGFR2-20-GORE 20 (40 μL) 200 μL
VCL-FGFR2-20-GOOR 20 (40 μL) 200 μL
VCL-FGFR2-20-GOGO 20 (40 μL) 200 μL
VCL-FGFR2-20-GOGR 20 (40 μL) 200 μL
VCL-FGFR2-20-GOAQ 20 (40 μL) 200 μL
VCL-FGFR2-20-GRRE 20 (40 μL) 200 μL
VCL-FGFR2-20-GROR 20 (40 μL) 200 μL
VCL-FGFR2-20-GRGO 20 (40 μL) 200 μL
VCL-FGFR2-20-GRGR 20 (40 μL) 200 μL
VCL-FGFR2-20-GRAQ 20 (40 μL) 200 μL
VCL-FGFR2-20-AQRE 20 (40 μL) 200 μL
VCL-FGFR2-20-AQOR 20 (40 μL) 200 μL
VCL-FGFR2-20-AQGO 20 (40 μL) 200 μL
VCL-FGFR2-20-AQGR 20 (40 μL) 200 μL
VCL-FGFR2-20-AQAQ 20 (40 μL) 200 μL

FGFR2 Gene Summary

The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jan 2009]

Gene Name: Fibroblast Growth Factor Receptor 2

Chromosome: CHR10: 123237843 -123357972

Locus: 10q26.13

VCL Gene Summary

Vinculin is a cytoskeletal protein associated with cell-cell and cell-matrix junctions, where it is thought to function as one of several interacting proteins involved in anchoring F-actin to the membrane. Defects in VCL are the cause of cardiomyopathy dilated type 1W. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Multiple alternatively spliced transcript variants have been found for this gene, but the biological validity of some variants has not been determined. [provided by RefSeq, Jul 2008]

Gene Name: Vinculin

Chromosome: CHR10: 75757871 -75879914

Locus: 10q22.2

Gene Diseases

The VCL FGFR2 Fusion has been associated with the following diseases:

Disease Name
Thyroid Carcinoma

FISH Probe Protocols

Protocol, Procedure, or Form Name Last Modified Download

FGFR2 amplification in colorectal adenocarcinoma

FGFR2 amplification occurs in about 5% of gastric cancers, but so far has only been reported in one colorectal cancer (CRC) cell line, where the cells were found to require FGFR2 amplification for survival. This was the first report of FGFR2 amplification in a CRC biopsy obtained directly from a patient’s primary tumor. Our FGFR2 FISH probe helped confirm FGFR2 amplification in the subject.